



PORTOLA®
PHARMACEUTICALS

Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

July 3, 2018

SOUTH SAN FRANCISCO, Calif., July 03, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that on June 27, 2018, the Compensation Committee of the Board of Directors approved, effective as of June 29, 2018, the grant of an inducement stock option to purchase 87,500 shares of common stock and an award in the form of 25,000 restricted stock units to Glenn Brame, the Company's newly appointed Senior Vice President, Technical Operations.

The stock option shall have an exercise price per share of \$37.77, the closing price per share of the Company's Common Stock on June 29, 2018, and will vest over four years, with 25 percent of the shares vesting on June 25, 2019, the one-year anniversary of the vesting commencement date, and the remaining shares vesting ratably over the subsequent 36 months, subject to Mr. Brame's continued service with the Company. The stock option has a ten-year term and is subject to the terms and conditions of the Company's Inducement Plan and the stock option agreement pursuant to which the option was granted. The shares subject to the restricted stock unit award shall vest in three equal annual installments over three years, with the first installment vesting on September 1, 2019, in each case subject to Mr. Brame's continued service with the Company.

The awards were granted as inducements material to Mr. Brame entering into employment with Portola in accordance with NASDAQ Listing Rule 5635(c)(4).

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic diseases. The Company's two FDA-approved medicines are Bevyxxa® (betrixaban), the first and only oral, once-daily Factor Xa inhibitor, and Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote for the Factor Xa inhibitors rivaroxaban and apixaban. The company also is advancing cerdulatinib, a Syk/JAK inhibitor for the treatment of hematologic cancers.

Investor Contact:

Cara Miller
Portola Pharmaceuticals
ir@portola.com

Media Contact:

Laurie Masonson
Pure Communications
lmasonson@purecommunications.com



Portola Pharmaceuticals, Inc.